Lucid Diagnostics (NASDAQ:LUCD) Raised to “Hold” at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities analysts also recently issued reports on LUCD. Ascendiant Capital Markets raised their price target on Lucid Diagnostics from $7.50 to $7.75 and gave the stock a “buy” rating in a research note on Friday, June 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $2.00 target price on shares of Lucid Diagnostics in a report on Thursday, May 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $3.55.

Lucid Diagnostics Stock Up 4.0%

LUCD stock opened at $1.02 on Friday. Lucid Diagnostics has a twelve month low of $0.73 and a twelve month high of $1.80. The firm has a market cap of $110.65 million, a PE ratio of -0.86 and a beta of 1.21. The business has a 50 day moving average of $1.12 and a 200 day moving average of $1.26.

Hedge Funds Weigh In On Lucid Diagnostics

A number of large investors have recently bought and sold shares of LUCD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Lucid Diagnostics during the second quarter worth $43,000. Invesco Ltd. acquired a new position in shares of Lucid Diagnostics during the second quarter worth $41,000. New York State Common Retirement Fund acquired a new position in shares of Lucid Diagnostics during the second quarter worth $97,000. Quadrature Capital Ltd acquired a new position in shares of Lucid Diagnostics during the second quarter worth $29,000. Finally, JPMorgan Chase & Co. increased its position in shares of Lucid Diagnostics by 71,026.1% during the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after purchasing an additional 32,672 shares in the last quarter. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.